Ignite Creation Date:
2024-05-06 @ 2:38 AM
Last Modification Date:
2024-10-26 @ 11:21 AM
Study NCT ID:
NCT02095964
Status:
COMPLETED
Last Update Posted:
2014-03-26
First Post:
2014-03-17
Brief Title:
HDL-C in Cardiac Syndrome X
Sponsor:
Bursa Yüksek İhtisas Education and Research Hospital
Organization:
Bursa Yüksek İhtisas Education and Research Hospital
Study Overview
Official Title:
HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HIRICS-X
Brief Summary:
High density lipoprotein cholesterol HDL-C is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver10 HDL-C promotes endothelial generation of nitric oxide NO and improves endothelial function and arterial vasoreactivity11 In several studies lower HDL-C level was reported to be associated with increased coronary artery disease CAD risk12-14 HDL-C also has anti- inflammatory and anti-oxidant activities1516 Concerning anti-inflammatory activity HDL-C inhibits the activation of monocytesmacrophages and neutrophils1718 and inhibits the expression of endothelial adhesion molecules such as vascular cell adhesion molecule-1 VCAM-1 and E-selectin15
In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X CSX
In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X CSX
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None